Comparison of New-Onset Diabetes After Kidney Transplant Between Hispanics and Caucasians Treated With Tacrolimus-Based Immunosuppression.

New-onset diabetes after kidney transplant (NODAT) significantly increases acute rejection, graft loss and mortality. Several risk factors for NODAT have been reported including: older age, obesity, hepatitis C infection, Hispanic or African American ethnicity, and use of calcineurin inhibitors and corticosteroids. The incidence and impact of NODAT in the Hispanic kidney transplant population is unknown. PATIENTS and METHODS: We retrospectively reviewed 155 Hispanics and 125 Caucasian patients who were not diabetics and underwent a first kidney transplant between January 2006 and December 2011. NODAT was diagnosed according to the WHO/ADA diabetes guidelines. We analyzed the incidence of NODAT, and patient and graft survival 12 months post-transplant. Analyses were performed using IBM SPSS v22; t-tests for continuous data and chi-square tests for categorical data. RESULTS:No significant differences between BMI and incidence of hepatitis C infection were found between the groups. (Table Presented) CONCLUSION: The incidence of NODAT is not significantly different between Hispanics and Caucasians treated with tacrolimus. Multicenter, prospective and long-term follow-up clinical trials are needed to validate these findings.